-
1
-
-
0032428533
-
Surface marker abnormalities in myelodysplastic syndromes
-
Elghetany MT. Surface marker abnormalities in myelodysplastic syndromes. Hematologica 1998; 83: 1104-1115.
-
(1998)
Hematologica
, vol.83
, pp. 1104-1115
-
-
Elghetany, M.T.1
-
2
-
-
15744378112
-
Immunophenotyping of acute leukemias
-
Bene MC. Immunophenotyping of acute leukemias. Immunol Lett 2005; 98: 9-21.
-
(2005)
Immunol Lett
, vol.98
, pp. 9-21
-
-
Bene, M.C.1
-
3
-
-
0035874549
-
Targeting of B7-1 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells
-
Notter M, Willinger T, Erben U, Thiel E. Targeting of B7-1 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells. Blood 2001; 97: 3138-3145.
-
(2001)
Blood
, vol.97
, pp. 3138-3145
-
-
Notter, M.1
Willinger, T.2
Erben, U.3
Thiel, E.4
-
4
-
-
0032840063
-
Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: Possible implications for future therapeutic strategies
-
Bruserud O. Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: Possible implications for future therapeutic strategies. Leukemia 1999; 13: 1175-1178.
-
(1999)
Leukemia
, vol.13
, pp. 1175-1178
-
-
Bruserud, O.1
-
5
-
-
0026688428
-
Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor beta 1 and cancer chemotherapy compounds in myeloid leukemia cells
-
Lotem J, Sachs L. Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor beta 1 and cancer chemotherapy compounds in myeloid leukemia cells. Blood 1992; 80: 1750-1757.
-
(1992)
Blood
, vol.80
, pp. 1750-1757
-
-
Lotem, J.1
Sachs, L.2
-
6
-
-
36049003710
-
Potential target antigens for immunotherapy identified by serological expression cloning (SEREX)
-
Jager D. Potential target antigens for immunotherapy identified by serological expression cloning (SEREX). Methods Mol Biol 2007; 360:319-326.
-
(2007)
Methods Mol Biol
, vol.360
, pp. 319-326
-
-
Jager, D.1
-
7
-
-
0026091624
-
The molecular pathology of chronic myelogengus leukemia
-
Kurzrock R, Talpaz M. The molecular pathology of chronic myelogengus leukemia. Br J Hematol 1991; 79: 34-37.
-
(1991)
Br J Hematol
, vol.79
, pp. 34-37
-
-
Kurzrock, R.1
Talpaz, M.2
-
8
-
-
33750043474
-
BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes
-
Kessler JH, Bres-Vlooemans-SA, van Veelen PA, de Ru A, Huijbers IJ, Camps M et al. BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes. Leukemia 2006; 20: 1738-1750.
-
(2006)
Leukemia
, vol.20
, pp. 1738-1750
-
-
Kessler, J.H.1
Vlooemans-SA, B.2
van Veelen, P.A.3
de Ru, A.4
Huijbers, I.J.5
Camps, M.6
-
9
-
-
0029002248
-
Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules
-
Bocchia M, Wentworth PA, Southwood S, Sidney J, McGraw K, Scheinberg DA et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 1995; 85: 2680-2684.
-
(1995)
Blood
, vol.85
, pp. 2680-2684
-
-
Bocchia, M.1
Wentworth, P.A.2
Southwood, S.3
Sidney, J.4
McGraw, K.5
Scheinberg, D.A.6
-
10
-
-
0029870222
-
Specific human cellular immunity to bcr-abl-oncogene-derived peptides
-
Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A et al Specific human cellular immunity to bcr-abl-oncogene-derived peptides. Blood 1996; 87: 3187-3392.
-
(1996)
Blood
, vol.87
, pp. 3187-3392
-
-
Bocchia, M.1
Korontsvit, T.2
Xu, Q.3
Mackinnon, S.4
Yang, S.Y.5
Sette, A.6
-
11
-
-
0035892131
-
Direct evidence that leukemia cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein
-
Clark RE, Dodi IA, Hill SC, Lill JR, Aubert G, Macintyre AR et al. Direct evidence that leukemia cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 2001; 98: 2887-2893.
-
(2001)
Blood
, vol.98
, pp. 2887-2893
-
-
Clark, R.E.1
Dodi, I.A.2
Hill, S.C.3
Lill, J.R.4
Aubert, G.5
Macintyre, A.R.6
-
12
-
-
20444378186
-
Ex vivo characterization of multiepitopic tumor specific CD8 T cells in patients with chronic myeloid leukemia: Implications for vaccine development and cellular immunotherapy
-
Gannage M, Abel M, Michaellet AS, Delluc S, Iambert M, Giraudier S et al. Ex vivo characterization of multiepitopic tumor specific CD8 T cells in patients with chronic myeloid leukemia: Implications for vaccine development and cellular immunotherapy. J Immunol 2005; 174: 8210-8218.
-
(2005)
J Immunol
, vol.174
, pp. 8210-8218
-
-
Gannage, M.1
Abel, M.2
Michaellet, A.S.3
Delluc, S.4
Iambert, M.5
Giraudier, S.6
-
13
-
-
0034161533
-
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint peptides generates specific immune responses
-
Pinilla-Ibarz J, Cathcart K, Krontsvit T, Soignet S, Bocchia M, Caggiano J et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint peptides generates specific immune responses. Blood 2000; 95: 1781-1787.
-
(2000)
Blood
, vol.95
, pp. 1781-1787
-
-
Pinilla-Ibarz, J.1
Cathcart, K.2
Krontsvit, T.3
Soignet, S.4
Bocchia, M.5
Caggiano, J.6
-
14
-
-
0026560593
-
The translocation (6;9) associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia specific dek-can mRNA
-
von Lindern M, Fornerod M, van Baal S, Jaegle M, de Wit T, Buijs A et al. The translocation (6;9) associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia specific dek-can mRNA. Mol Cell Biol 1992; 12: 1687-1697.
-
(1992)
Mol Cell Biol
, vol.12
, pp. 1687-1697
-
-
von Lindern, M.1
Fornerod, M.2
van Baal, S.3
Jaegle, M.4
de Wit, T.5
Buijs, A.6
-
15
-
-
0025875679
-
-
de The' H, Lavau C, Marchino A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991; 66: 675-684.
-
de The' H, Lavau C, Marchino A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991; 66: 675-684.
-
-
-
-
16
-
-
0027180828
-
An AML1/ETO fusion transcript is consistently detected by RNA based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation
-
Downing JR, Head Dr, Curcio-Brint AM, Hulshof MG, Motroni TA, Raimondi SC et al. An AML1/ETO fusion transcript is consistently detected by RNA based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation. Blood 1993; 81 2860-2865.
-
(1993)
Blood
, vol.81
, pp. 2860-2865
-
-
Downing, J.R.1
Head, D.2
Curcio-Brint, A.M.3
Hulshof, M.G.4
Motroni, T.A.5
Raimondi, S.C.6
-
17
-
-
0027403209
-
Human CD4 lymphocytes specifically recognize a peptide representing a fusion region of the hybrid protein pml/RARalpha present in acute promyelocytic leukemia cells
-
Gambacorti-Passerini C, Grignani F, Arienti F, Pandolfi PP, Pelicci PG, Parmiani G. Human CD4 lymphocytes specifically recognize a peptide representing a fusion region of the hybrid protein pml/RARalpha present in acute promyelocytic leukemia cells. Blood 1993; 81: 1369-1375.
-
(1993)
Blood
, vol.81
, pp. 1369-1375
-
-
Gambacorti-Passerini, C.1
Grignani, F.2
Arienti, F.3
Pandolfi, P.P.4
Pelicci, P.G.5
Parmiani, G.6
-
18
-
-
0026644858
-
Structure, chromosomal assignment, and expression of the gene for proteinase-3. The Wegener's granulomatosis autoantigen
-
Sturrock AB, Franklin KF, Rao G, Marshall BC, Rebentisch MB, Lemons RS et al. Structure, chromosomal assignment, and expression of the gene for proteinase-3. The Wegener's granulomatosis autoantigen. J Biol Chem 1992; 267: 1193-1199.
-
(1992)
J Biol Chem
, vol.267
, pp. 1193-1199
-
-
Sturrock, A.B.1
Franklin, K.F.2
Rao, G.3
Marshall, B.C.4
Rebentisch, M.B.5
Lemons, R.S.6
-
19
-
-
0028213154
-
Myeloblastin/proteinase 3 belongs to the set of negatively regulated primary response genes expressed during in vitro myeloid differentiation
-
Chen T, Meier R, Ziemiecki A, Fey MF, Tobler A. Myeloblastin/proteinase 3 belongs to the set of negatively regulated primary response genes expressed during in vitro myeloid differentiation. Biochem Biophys Res Commun 1994; 200: 1130-1135.
-
(1994)
Biochem Biophys Res Commun
, vol.200
, pp. 1130-1135
-
-
Chen, T.1
Meier, R.2
Ziemiecki, A.3
Fey, M.F.4
Tobler, A.5
-
20
-
-
0028153951
-
The phylogeny of proteinase 3/myeloblastin, the autoantigen in Wegener's granulomatosis, a myeloperoxidase as shown by immunohistochemical studies on human leukemia cell lines
-
Muller-Berat N, Minowada J, Tsuji-Takayama K, Drexler H, Lanotte M, Wieslander J et al. The phylogeny of proteinase 3/myeloblastin, the autoantigen in Wegener's granulomatosis, a myeloperoxidase as shown by immunohistochemical studies on human leukemia cell lines. Clin Immunol Immunopathol 1994; 70: 51-59.
-
(1994)
Clin Immunol Immunopathol
, vol.70
, pp. 51-59
-
-
Muller-Berat, N.1
Minowada, J.2
Tsuji-Takayama, K.3
Drexler, H.4
Lanotte, M.5
Wieslander, J.6
-
21
-
-
0024817730
-
Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells
-
Bories D, Raynal MC, Solomon DH, Darzynkiewicz Z, Cayre YE. Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells. Cell 1989; 59: 959-968.
-
(1989)
Cell
, vol.59
, pp. 959-968
-
-
Bories, D.1
Raynal, M.C.2
Solomon, D.H.3
Darzynkiewicz, Z.4
Cayre, Y.E.5
-
22
-
-
0030997435
-
Granules of human neutrophilic polymorphonuclear leukocytes
-
Borregaard N, Cowland JB. Granules of human neutrophilic polymorphonuclear leukocytes. Blood 1997; 89: 3503-3521.
-
(1997)
Blood
, vol.89
, pp. 3503-3521
-
-
Borregaard, N.1
Cowland, J.B.2
-
23
-
-
0028077538
-
T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis
-
Brouwer E, Stageman CA, Huitema MG, Limburg PC, Kallenberg CG. T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis. Clin Exp Immunol 1994; 98: 448-453.
-
(1994)
Clin Exp Immunol
, vol.98
, pp. 448-453
-
-
Brouwer, E.1
Stageman, C.A.2
Huitema, M.G.3
Limburg, P.C.4
Kallenberg, C.G.5
-
24
-
-
0034091281
-
Antiproteinase 3- and myeloperoxidase-associated vasculitis
-
Franssen CF, Stageman CA, Kallenberg CG, Gans RO, De Jong PE, Hoorntje SJ et al. Antiproteinase 3- and myeloperoxidase-associated vasculitis. Kidney Int 2000; 57: 2195-2206.
-
(2000)
Kidney Int
, vol.57
, pp. 2195-2206
-
-
Franssen, C.F.1
Stageman, C.A.2
Kallenberg, C.G.3
Gans, R.O.4
De Jong, P.E.5
Hoorntje, S.J.6
-
25
-
-
0029838112
-
Targeted T-cell therapy for human leukemia: Cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells
-
Molldrem J, Dermime S, Parker K, Jiang YZ, Mavroudis D, Hensel N et al. Targeted T-cell therapy for human leukemia: Cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 1996; 88: 2450-2457.
-
(1996)
Blood
, vol.88
, pp. 2450-2457
-
-
Molldrem, J.1
Dermime, S.2
Parker, K.3
Jiang, Y.Z.4
Mavroudis, D.5
Hensel, N.6
-
26
-
-
0030841573
-
Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony forming units
-
Molldrem J, Clave E, Jiang YZ, Mavroudis D, Raptis A, Hensel N et al Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony forming units. Blood 1997; 90: 2529-2534.
-
(1997)
Blood
, vol.90
, pp. 2529-2534
-
-
Molldrem, J.1
Clave, E.2
Jiang, Y.Z.3
Mavroudis, D.4
Raptis, A.5
Hensel, N.6
-
27
-
-
0033152972
-
A PR1-human leukocyte antigen A2 tertramer can be used to isolate low frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chromic myelogenous leukemia
-
Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. A PR1-human leukocyte antigen A2 tertramer can be used to isolate low frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chromic myelogenous leukemia. Cancer Res 1999; 59: 2675-2681.
-
(1999)
Cancer Res
, vol.59
, pp. 2675-2681
-
-
Molldrem, J.J.1
Lee, P.P.2
Wang, C.3
Champlin, R.E.4
Davis, M.M.5
-
28
-
-
33746888125
-
Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancer
-
Oka Y, Tsuboi A, Kawakami M, Elisseeva OA, Nakajima H, Udaka K et al Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancer. Curr Med Chem 2006; 13: 2345-2352.
-
(2006)
Curr Med Chem
, vol.13
, pp. 2345-2352
-
-
Oka, Y.1
Tsuboi, A.2
Kawakami, M.3
Elisseeva, O.A.4
Nakajima, H.5
Udaka, K.6
-
29
-
-
0032522925
-
Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells
-
Inoue K, Tamaki H, Ogawa H, Oka Y, Soma T, Tatekawa T et al. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 1998; 91: 2969-2976.
-
(1998)
Blood
, vol.91
, pp. 2969-2976
-
-
Inoue, K.1
Tamaki, H.2
Ogawa, H.3
Oka, Y.4
Soma, T.5
Tatekawa, T.6
-
30
-
-
0032944068
-
Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF)
-
Tsuboi A, Oka Y, Ogawa H, Elisseeva OA, Tamaki H, Oji Y et al. Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). Leuk Res 1999; 23: 499-505.
-
(1999)
Leuk Res
, vol.23
, pp. 499-505
-
-
Tsuboi, A.1
Oka, Y.2
Ogawa, H.3
Elisseeva, O.A.4
Tamaki, H.5
Oji, Y.6
-
31
-
-
0033966369
-
HLA class I-restricted lysis of leukemia cells by CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide
-
Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000; 93: 286-293.
-
(2000)
Blood
, vol.93
, pp. 286-293
-
-
Ohminami, H.1
Yasukawa, M.2
Fujita, S.3
-
32
-
-
0034176750
-
Selective elimination of leukemia CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1
-
Gao L, Ballantuono I, Elsasser A, Marley SB, Gordon MY, Goldman JM et al. Selective elimination of leukemia CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000; 95: 2198-2203.
-
(2000)
Blood
, vol.95
, pp. 2198-2203
-
-
Gao, L.1
Ballantuono, I.2
Elsasser, A.3
Marley, S.B.4
Gordon, M.Y.5
Goldman, J.M.6
-
33
-
-
0035577861
-
Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals
-
Vonderheide RH, Schultze JL, Anderson KS, maecker B, Butler MO, Xia Z et al. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res 2001; 61: 8366-8370.
-
(2001)
Cancer Res
, vol.61
, pp. 8366-8370
-
-
Vonderheide, R.H.1
Schultze, J.L.2
Anderson, K.S.3
maecker, B.4
Butler, M.O.5
Xia, Z.6
-
34
-
-
0035881885
-
Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients
-
Andersen MH, Pedersen LO, Capeller B, Bröker EB, Becker JC, thor Straten P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 2001; 61 5964-5968.
-
(2001)
Cancer Res
, vol.61
, pp. 5964-5968
-
-
Andersen, M.H.1
Pedersen, L.O.2
Capeller, B.3
Bröker, E.B.4
Becker, J.C.5
thor Straten, P.6
-
35
-
-
0037818503
-
Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells
-
Schmidt SM, Schag K, Muller MR, Weck MM, Appel S, Kanz L et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003; 102: 571-576.
-
(2003)
Blood
, vol.102
, pp. 571-576
-
-
Schmidt, S.M.1
Schag, K.2
Muller, M.R.3
Weck, M.M.4
Appel, S.5
Kanz, L.6
-
36
-
-
0031671357
-
Polymorphism in CD33 and CD34 genes: A source of minor histocompatibility antigens on haematopoietic progenitor cells?
-
Raptis A, Clave E, Mavroudis D, Molldrem J, Van Rhee F, Barrett AJ. Polymorphism in CD33 and CD34 genes: A source of minor histocompatibility antigens on haematopoietic progenitor cells? Br J Haematol 1998; 102: 1354-1358.
-
(1998)
Br J Haematol
, vol.102
, pp. 1354-1358
-
-
Raptis, A.1
Clave, E.2
Mavroudis, D.3
Molldrem, J.4
Van Rhee, F.5
Barrett, A.J.6
-
37
-
-
0037305594
-
Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity
-
Amrolia PJ, Reid SD, Gao, L, Schultheis B, Dotti G, Brenner MK et al Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity. Blood 2003; 101: 1007-1014.
-
(2003)
Blood
, vol.101
, pp. 1007-1014
-
-
Amrolia, P.J.1
Reid, S.D.2
Gao, L.3
Schultheis, B.4
Dotti, G.5
Brenner, M.K.6
-
38
-
-
0026645959
-
A nanopeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigens MZ2-E
-
Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A et al. A nanopeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigens MZ2-E. J Exp Med 1992; 176: 1453-1457.
-
(1992)
J Exp Med
, vol.176
, pp. 1453-1457
-
-
Traversari, C.1
van der Bruggen, P.2
Luescher, I.F.3
Lurquin, C.4
Chomez, P.5
Van Pel, A.6
-
39
-
-
0028952240
-
BAGE: A new gene encoding an antigen recognized on human melanoma by cytolytic T lymphocytes
-
Boel P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P et al BAGE: A new gene encoding an antigen recognized on human melanoma by cytolytic T lymphocytes. Immunity 1995; 2: 167-175.
-
(1995)
Immunity
, vol.2
, pp. 167-175
-
-
Boel, P.1
Wildmann, C.2
Sensi, M.L.3
Brasseur, R.4
Renauld, J.C.5
Coulie, P.6
-
40
-
-
0034541547
-
Simultaneous expression of different immunogenic antigens in acute myeloid leukemia
-
Greiner J, Ronghoffer M, Simikopinko O, Szmaraqowska A, Huebsch S, Maurer U et al. Simultaneous expression of different immunogenic antigens in acute myeloid leukemia. Exp Hematol 2000; 28: 1413-1422.
-
(2000)
Exp Hematol
, vol.28
, pp. 1413-1422
-
-
Greiner, J.1
Ronghoffer, M.2
Simikopinko, O.3
Szmaraqowska, A.4
Huebsch, S.5
Maurer, U.6
-
41
-
-
0035883073
-
Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphocyte progression
-
Sotomayor EM, Borrello I, Rattis FM, Cuenca AG, Abrams J, Steveley-O'Carroll K et al. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphocyte progression. Blood 2001; 98: 1070-1077.
-
(2001)
Blood
, vol.98
, pp. 1070-1077
-
-
Sotomayor, E.M.1
Borrello, I.2
Rattis, F.M.3
Cuenca, A.G.4
Abrams, J.5
Steveley-O'Carroll, K.6
-
42
-
-
0030319698
-
Tolerance and cancer: A critical issue in tumor immunology
-
Sotomayor EM, Borrello I, Levitsky HI. Tolerance and cancer: A critical issue in tumor immunology. Crit Rev Oncol 1996; 7: 433-456.
-
(1996)
Crit Rev Oncol
, vol.7
, pp. 433-456
-
-
Sotomayor, E.M.1
Borrello, I.2
Levitsky, H.I.3
-
43
-
-
0029870222
-
Specific human cellular immunity to bcr-abl oncogene-derived peptides
-
Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A et al Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996; 87: 3587-3592.
-
(1996)
Blood
, vol.87
, pp. 3587-3592
-
-
Bocchia, M.1
Korontsvit, T.2
Xu, Q.3
Mackinnon, S.4
Yang, S.Y.5
Sette, A.6
-
44
-
-
1642500316
-
A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia
-
Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos EB et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004; 103: 1037-1042.
-
(2004)
Blood
, vol.103
, pp. 1037-1042
-
-
Cathcart, K.1
Pinilla-Ibarz, J.2
Korontsvit, T.3
Schwartz, J.4
Zakhaleva, V.5
Papadopoulos, E.B.6
-
45
-
-
13844312036
-
Effect of p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: A multicentre observational trial
-
Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A et al. Effect of p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: A multicentre observational trial. Lancet 2005; 365: 657-662.
-
(2005)
Lancet
, vol.365
, pp. 657-662
-
-
Bocchia, M.1
Gentili, S.2
Abruzzese, E.3
Fanelli, A.4
Iuliano, F.5
Tabilio, A.6
-
46
-
-
0742324477
-
Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity
-
Mailaender V, Scheibenbogen C, Thiel E, Letsch A, Blau IW, Keilholz U. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 2004; 18: 165-166.
-
(2004)
Leukemia
, vol.18
, pp. 165-166
-
-
Mailaender, V.1
Scheibenbogen, C.2
Thiel, E.3
Letsch, A.4
Blau, I.W.5
Keilholz, U.6
-
47
-
-
51649126893
-
-
Letsch A, Scheibenbogen C, Busse A, Asemissen A, Schmittel WK, Hofmann L et al. Phase II trial of vaccination with WT1 peptide, GM-CSF, and KHL in patients with acute myeloid leukemia and myelodysplasia: Final immunological, molecular, and clinical results. Abstract J Clin Oncol 2007; 25: 3800 (Abstract No. 3008).
-
Letsch A, Scheibenbogen C, Busse A, Asemissen A, Schmittel WK, Hofmann L et al. Phase II trial of vaccination with WT1 peptide, GM-CSF, and KHL in patients with acute myeloid leukemia and myelodysplasia: Final immunological, molecular, and clinical results. Abstract J Clin Oncol 2007; 25: 3800 (Abstract No. 3008).
-
-
-
-
48
-
-
20444448873
-
Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia
-
Li Z, Qiao Y, Liu B, Laska EJ, Chakravarthi P, Kulko JM et al. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin Cancer Res 2005; 11: 4460-4468.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 4460-4468
-
-
Li, Z.1
Qiao, Y.2
Liu, B.3
Laska, E.J.4
Chakravarthi, P.5
Kulko, J.M.6
-
49
-
-
0028179056
-
Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
-
Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994; 264: 961-965.
-
(1994)
Science
, vol.264
, pp. 961-965
-
-
Huang, A.Y.1
Golumbek, P.2
Ahmadzadeh, M.3
Jaffee, E.4
Pardoll, D.5
Levitsky, H.6
-
50
-
-
0029864363
-
Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?
-
Huang AY, Bruce AT, Pardoll DM, Levitsky H. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med 1996; 183: 769-776.
-
(1996)
J Exp Med
, vol.183
, pp. 769-776
-
-
Huang, A.Y.1
Bruce, A.T.2
Pardoll, D.M.3
Levitsky, H.4
-
51
-
-
0027538181
-
Vaccination with irradiated tumor cells engineered to express granulocyte-macrophage colony stimulating factor stimulates potent, specific, and long-lasting antitumor immunity
-
Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K et al Vaccination with irradiated tumor cells engineered to express granulocyte-macrophage colony stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
-
(1993)
Proc Natl Acad Sci USA
, vol.90
, pp. 3539-3543
-
-
Dranoff, G.1
Jaffee, E.2
Lazenby, A.3
Golumbek, P.4
Levitsky, H.5
Brose, K.6
-
52
-
-
0029963944
-
Immunization with granulocyte-macrophage colony stimulating factor transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific immune responses and generates potent systemic antitumor immunity
-
evitsky HI, Montgomery J, Ahmedzahed M, Staveley-O'Carroll K, Guarnieri F, Longo DM et al. Immunization with granulocyte-macrophage colony stimulating factor transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific immune responses and generates potent systemic antitumor immunity. J Immunol 1996; 156: 3858-3865.
-
(1996)
J Immunol
, vol.156
, pp. 3858-3865
-
-
evitsky, H.I.1
Montgomery, J.2
Ahmedzahed, M.3
Staveley-O'Carroll, K.4
Guarnieri, F.5
Longo, D.M.6
-
53
-
-
0033543076
-
A universal granulocyte-macrophage colony stimulating factor-producing by-stander cell line for the use in the formulation of formulation of tumor cell based vaccines
-
Borrello I, Sotomayor EM, Cooke S, Levitsky H. A universal granulocyte-macrophage colony stimulating factor-producing by-stander cell line for the use in the formulation of formulation of tumor cell based vaccines. Hum Gene Ther 1999; 10: 1983-1991.
-
(1999)
Hum Gene Ther
, vol.10
, pp. 1983-1991
-
-
Borrello, I.1
Sotomayor, E.M.2
Cooke, S.3
Levitsky, H.4
-
54
-
-
51649098640
-
-
Smith BD, Kasamon YL, Miller CB, Chia CY, Murphy K, Kowalski J et al K562/GM-CSF vaccination reduces tumor burden, including achieving molecular remissions, in chronic myeloid leukemia (CML) patients with residual disease on imatinib mesylate (IM). American society of hematology annual meeting. Blood 2005; 106: 801 a (Abstract No. 6509).
-
Smith BD, Kasamon YL, Miller CB, Chia CY, Murphy K, Kowalski J et al K562/GM-CSF vaccination reduces tumor burden, including achieving molecular remissions, in chronic myeloid leukemia (CML) patients with residual disease on imatinib mesylate (IM). American society of hematology annual meeting. Blood 2005; 106: 801 a (Abstract No. 6509).
-
-
-
-
55
-
-
34848865393
-
T-cell therapy after hematopoietic stem cell transplantation
-
Kennedy-Nasser AA, Brenner MK. T-cell therapy after hematopoietic stem cell transplantation. Curr Opin Hematol 2007; 14: 616-624.
-
(2007)
Curr Opin Hematol
, vol.14
, pp. 616-624
-
-
Kennedy-Nasser, A.A.1
Brenner, M.K.2
-
56
-
-
33846828702
-
Natural killer cell alloreactivity in allogeneic transplantation
-
Ruggeri M, Mancusi A, Burchielli E, Capanni M, Carotti A, Aloisi T et al. Natural killer cell alloreactivity in allogeneic transplantation. Curr Opin Oncol 2007; 19: 142-147.
-
(2007)
Curr Opin Oncol
, vol.19
, pp. 142-147
-
-
Ruggeri, M.1
Mancusi, A.2
Burchielli, E.3
Capanni, M.4
Carotti, A.5
Aloisi, T.6
-
57
-
-
33745504341
-
Function of natural killer cells in immune defense against human leukemia
-
Wodnar-Filipowicz A, Kalberer CP. Function of natural killer cells in immune defense against human leukemia. Swiss Med Wkly 2006; 136 359-364.
-
(2006)
Swiss Med Wkly
, vol.136
, pp. 359-364
-
-
Wodnar-Filipowicz, A.1
Kalberer, C.P.2
-
59
-
-
34548585368
-
The use of hypomethylating agents in the treatment of hematological malignancies
-
Kihslinger JE, Godley LA. The use of hypomethylating agents in the treatment of hematological malignancies. Leuk Lymphoma 2007; 48 1676-1695.
-
(2007)
Leuk Lymphoma
, vol.48
, pp. 1676-1695
-
-
Kihslinger, J.E.1
Godley, L.A.2
-
60
-
-
33847216496
-
Vascular endothelial growth factor and its receptors as drug targets in hematological malignancies
-
Kessler T, Fehrmann F, Bieker R, Berdel WE, Mesters RM. Vascular endothelial growth factor and its receptors as drug targets in hematological malignancies. Curr Drug Targets 2007; 8: 257-268.
-
(2007)
Curr Drug Targets
, vol.8
, pp. 257-268
-
-
Kessler, T.1
Fehrmann, F.2
Bieker, R.3
Berdel, W.E.4
Mesters, R.M.5
|